Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 30, Issue 3, 2013, Pages 201-211

  Drake, Wonder P ^a   Richmond, B W ^a   Oswald Richter, K ^a   Yu, C ^a   Isom, J M ^a   Worrell, J A ^a   Shipley, R ^b   Bernard, G R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Antibiotics; Clinical trial; Sarcoidosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; ETHAMBUTOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; PROTEIN KINASE LCK; RIFABUTIN; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIMICROBIAL THERAPY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SUBSTITUTION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; HEPATITIS; HUMAN; HYPOTENSION; IMMUNOTHERAPY; INSOMNIA; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LUNG SARCOIDOSIS; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SIX MINUTE WALK DISTANCE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT RESPONSE; CHRONIC OBSTRUCTIVE LUNG DISEASE;

AZITHROMYCIN; HUMANS; LEVOFLOXACIN; NF-KAPPA B; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SARCOIDOSIS, PULMONARY;

EID: 84896103214     PISSN: 11240490     EISSN: 2532179X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Swigris JJ, Olson AL, Huie TJ et al. Sarcoidosis-related Mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011; 183(11):1524-1530.
2. Baughman RP, Lynch JP. Difficult treatment issues in sarcoidosis. J InternMed 2003; 253(1):41-45.
3. Pietinalho A, Tukiainen P, Haahtela T et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest 1999; 116:424-431.
4. Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoido-sis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis 1979; 60(4):215-221.
5. Zaki MH, Lyons HA, Leilop L et al. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study.N Y State JMed 1987; 87(9):496-499.
6. Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010; 31(4):501-518.
7. Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174(7):795-802.
8. Lee NS, Barber L, Kanchwala A et al. Low levels of NF-kappaB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis. Clin Vaccine Immunol 2011; 18(2):223-234.
9. Zea AH, Ochoa MT, Ghosh P et al. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun 1998; 66(2):499-504.
10. Mahon RN, Sande OJ, Rojas RE et al. Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation. Cell Immunol 2012; 275(1-2):98-105.
11. Song Z, Marzilli L, Greenlee BM et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201(5):755-767.
12. Allen SS, Evans W, Carlisle J et al. Superoxide dismutase A antigens derived from molecular analysis of sarcoidosis granulomas elicit systemic Th-1 immune responses. Respir Res 2008; 9:36.
13. Oswald-Richter KA, Beachboard DC, Seeley EHet al.Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol 2012; 32(5):1129-1140.
14. Volkman HE, Pozos TC, Zheng J et al. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010; 327(5964):466-469.
15. Volkman HE, Clay H, Beery D et al.Tuberculous granuloma formation is enhanced by amycobacteriumvirulence determinant. PLoS Biol 2004; 2(11):e367.
16. Drake WP, Dhason MS, Nadaf M et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun 2007; 75(1):527-530.
17. Chen ES, Wahlstrom J, Song Z et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008; 181(12):8784-8796.
18. Lalvani A, Pathan AA, Durkan H et al. Enhanced contact tracing and spatial tracking ofMycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357(9273):2017-2021.
19. Sester U, Fousse M, Dirks J et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One 2011; 6(3):e17813.
20. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3(6):359-371.
21. Schmitt CE, Fabi SG, Kukreja T et al. Hypopigmented cutaneous sarcoidosis responsive to minocycline. J Drugs Dermatol 2012; 11(3):385-389.
22. Bachelez H, Senet P, Cadranel J et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137(1):69-73.
23. Drake WP, Pei Z, Pride DT et al. Molecular analysis of sarcoidosis tissues for mycobacterium species DNA. Emerg Infect Dis 2002;8(11):1334-1341.
24. Dauendorffer JN, Guillemin I, Aubry A et al. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J Clin Microbiol 2003; 41(3):1311-1315.
25. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175(4):367-416.
26. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167(4):603-662.
27. Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16(2):149-173.
28. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175(4):367-416.
29. Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur Respir J 2005; 26(2):319-338.
30. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1):111-117.
31. Oswald Richter KA, Richmond BW, Braun NA, Jsom J, Abraham S, Taylor TR, Drake JM, Culver DA,Wilkes DS, Drake WP. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis: J Immunol 2013; 190(11): 5446-53.
32. Gibson GJ, Prescott RJ, Muers MF et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51(3):238-247.
33. Pietinalho A, Tukiainen P, Haahtela T et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116(2):424-431.
34. Baculard A, Blanc N, Boule M et al. Pulmonary sarcoidosis in children: a follow-up study. Eur Respir J 2001; 17(4):628-635.
35. Ewer K, Millington KA, Deeks JJ et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174(7):831-839.
36. Chen ES, Wahlstrom J, Song Z et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008; 181(12):8784-8796.
37. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004; 84(1-2):29-44.
38. Munro SA, Lewin SA, Smith HJ et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4(7):e238.
39. Daley CL. Update in tuberculosis 2009. Am J Respir Crit Care Med 2010; 181(6):550-555.
40. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010; 33(5):353-369.
41. Cormican LJ, Schey S, Milburn HJ. G-CSF enables completion of tuberculosis therapy associated with iatrogenic neutropenia. Eur Respir J 2004; 23(4):649-650.
42. Berezhinskaia VV, Dolgova GV, Svinogeeva TP et al. [Mechanism of hypotension induced by rifampicin during intravenous administration]. Antibiot Khimioter 1988; 33(10):771-775.
43. Peng H, Wang X, Barnes PF et al. The Mycobacterium tuberculosis Early Secreted Antigenic Target of 6 kDa Inhibits T Cell Interferon-{gamma} Production through the p38 Mitogen-activated Protein Kinase Pathway. J Biol Chem 2011; 286(27):24508-24518.
44. Samten B, Wang X, Barnes PF. Mycobacterium tuberculosis ESX-1 system-secreted protein ESAT-6 but not CFP10 inhibits human T-cell immune responses.Tuberculosis (Edinb) 2009; 89 Suppl 1:S74-S76.
45. Millington KA, Innes JA, Hackforth S et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol 2007; 178(8):5217-5226.